• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

NIDA IRP

National Institute on Drug Abuse - Intramural Research Program

  National Institute on Drug Abuse | NIH IRP | Treatment Info | Emergency Contacts
  • Home
  • News
    • Featured Paper of the Month
    • Reviews to Read
    • Hot off the Press
    • IRP News
    • Awards
    • Technology Development Initiative Paper of the Month
    • Seminar Series
    • Addiction Grand Rounds
  • About
    • About NIDA IRP
    • Contact Us
    • Directions and Map
    • Careers at NIDA IRP
    • Emergency Contacts
    • Employee Assistance Resources
  • Organization
    • Faculty
    • Office of the Scientific Director
    • Office of the Clinical Director
    • Office of Education and Career Development
    • Administrative Management Branch
    • Molecular Targets and Medications Discovery Branch
    • Cellular and Neurocomputational Systems Branch
    • Molecular Neuropsychiatry Research Branch
    • Neuroimaging Research Branch
    • Behavioral Neuroscience Research Branch
    • Integrative Neuroscience Research Branch
    • Translational Addiction Medicine Branch
    • Core Facilities
    • Community Outreach Group
  • Training Programs
    • Office of Education and Career Development
    • OECD Awards
    • Summer Internship Program
    • Postbaccalaureate Program
    • Graduate Partnership Program
    • Postdoctoral Program
    • NIDA Speakers Bureau
    • Clinical Electives Program
    • Clinical Mentoring Program
  • Study Volunteers

Persistent binding at dopamine transporters determines sustained psychostimulant effects

A figure from this articleFeatured Paper of the Month – May 2023

Published in PNAS with contributions from Carl Lupica, Alexander Hoffman, and Michael Baumann of the NIDA IRP.

Summary

Pyrovalerone analogs, like αPVP (i.e., “flakka”) and MDPV (i.e., “bath salts”), are abused stimulant drugs that produce serious and sustained adverse effects in humans. It is well established that αPVP and MDPV bind to the dopamine transporter (DAT), but the precise time-course of drug binding has not been studied. Here we demonstrate that various DAT inhibitors can be distinguished based on their in vitro binding kinetics, whereby the dissociation rate (i.e., Koff) of a drug from DAT in vitro predicts the duration of its stimulant effects in vivo. In particular, we show that S-isomers of αPVP and MDPV display slow dissociation from DAT and sustained psychostimulant effects in mice, which differs from the fast in vitro kinetics and short-lived effects of drugs like cocaine. Our study provides key evidence that binding kinetics at DAT are an important, yet often overlooked, determinant of psychostimulant drug action.

Publication Information

Niello, Marco; Sideromenos, Spyridon; Gradisch, Ralph; Shea, Ronan O; Schwazer, Jakob; Maier, Julian; Kastner, Nina; Sandtner, Walter; Jäntsch, Kathrin; Lupica, Carl R; Hoffman, Alexander F; Lubec, Gert; Loland, Claus J; Stockner, Thomas; Pollak, Daniela D; Baumann, Michael H; Sitte, Harald H

Persistent binding at dopamine transporters determines sustained psychostimulant effects Journal Article

In: Proc Natl Acad Sci U S A, vol. 120, no. 6, pp. e2114204120, 2023, ISSN: 1091-6490.

Abstract | Links

@article{pmid36730201,
title = {Persistent binding at dopamine transporters determines sustained psychostimulant effects},
author = {Marco Niello and Spyridon Sideromenos and Ralph Gradisch and Ronan O Shea and Jakob Schwazer and Julian Maier and Nina Kastner and Walter Sandtner and Kathrin Jäntsch and Carl R Lupica and Alexander F Hoffman and Gert Lubec and Claus J Loland and Thomas Stockner and Daniela D Pollak and Michael H Baumann and Harald H Sitte},
url = {https://pubmed.ncbi.nlm.nih.gov/36730201/},
doi = {10.1073/pnas.2114204120},
issn = {1091-6490},
year = {2023},
date = {2023-02-01},
urldate = {2023-02-01},
journal = {Proc Natl Acad Sci U S A},
volume = {120},
number = {6},
pages = {e2114204120},
abstract = {Psychostimulants interacting with the dopamine transporter (DAT) can be used illicitly or for the treatment of specific neuropsychiatric disorders. However, they can also produce severe and persistent adverse events. Often, their pharmacological properties in vitro do not fully correlate to their pharmacological profile in vivo. Here, we investigated the pharmacological effects of enantiomers of pyrovalerone, α-pyrrolidinovalerophenone, and 3,4-methylenedioxypyrovalerone as compared to the traditional psychostimulants cocaine and methylphenidate, using a variety of in vitro, computational, and in vivo approaches. We found that in vitro drug-binding kinetics at DAT correlate with the time-course of in vivo psychostimulant action in mice. In particular, a slow dissociation (i.e., slow ) of -enantiomers of pyrovalerone analogs from DAT predicts their more persistent in vivo effects when compared to cocaine and methylphenidate. Overall, our findings highlight the critical importance of drug-binding kinetics at DAT for determining the in vivo profile of effects produced by psychostimulant drugs.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

Psychostimulants interacting with the dopamine transporter (DAT) can be used illicitly or for the treatment of specific neuropsychiatric disorders. However, they can also produce severe and persistent adverse events. Often, their pharmacological properties in vitro do not fully correlate to their pharmacological profile in vivo. Here, we investigated the pharmacological effects of enantiomers of pyrovalerone, α-pyrrolidinovalerophenone, and 3,4-methylenedioxypyrovalerone as compared to the traditional psychostimulants cocaine and methylphenidate, using a variety of in vitro, computational, and in vivo approaches. We found that in vitro drug-binding kinetics at DAT correlate with the time-course of in vivo psychostimulant action in mice. In particular, a slow dissociation (i.e., slow ) of -enantiomers of pyrovalerone analogs from DAT predicts their more persistent in vivo effects when compared to cocaine and methylphenidate. Overall, our findings highlight the critical importance of drug-binding kinetics at DAT for determining the in vivo profile of effects produced by psychostimulant drugs.

Close

  • https://pubmed.ncbi.nlm.nih.gov/36730201/
  • doi:10.1073/pnas.2114204120

Close

Primary Sidebar

News

  • All News and Featured Publications
  • Featured Paper of the Month
  • Hot off the Press
  • Reviews to Read
  • IRP News
  • Awards
  • Technology Development Initiative Paper of the Month
  • Seminar Series
Home / News Main / Featured Paper of the Month / Persistent binding at dopamine transporters determines sustained psychostimulant effects
  • National Institute on Drug Abuse
  • NIH Intramural Research Program
  • National Institutes of Health
  • Health and Human Services
  • USA.GOV
  • Emergency Contacts
  • Employee Assistance
  • Treatment Information
  • Contact Us
  • Careers at NIDA IRP
  • Accessibility
  • Privacy
  • HHS Vulnerability Disclosure
  • Freedom of Information Act
  • Document Viewing Tools
  • Offsite Links
  • National Institute on Drug Abuse
  • NIH Intramural Research Program
  • National Institutes of Health
  • Health and Human Services
  • USA.GOV
  • Emergency Contacts
  • Employee Assistance
  • Treatment Information
  • Contact Us
  • Careers at NIDA IRP
  • Accessibility
  • Privacy
  • HHS Vulnerability Disclosure
  • Freedom of Information Act
  • Document Viewing Tools
  • Offsite Links

  • Home
  • News
    ▼
    • Featured Paper of the Month
    • Reviews to Read
    • Hot off the Press
    • IRP News
    • Awards
    • Technology Development Initiative Paper of the Month
    • Seminar Series
    • Addiction Grand Rounds
  • About
    ▼
    • About NIDA IRP
    • Contact Us
    • Directions and Map
    • Careers at NIDA IRP
    • Emergency Contacts
    • Employee Assistance Resources
  • Organization
    ▼
    • Faculty
    • Office of the Scientific Director
    • Office of the Clinical Director
    • Office of Education and Career Development
    • Administrative Management Branch
    • Molecular Targets and Medications Discovery Branch
    • Cellular and Neurocomputational Systems Branch
    • Molecular Neuropsychiatry Research Branch
    • Neuroimaging Research Branch
    • Behavioral Neuroscience Research Branch
    • Integrative Neuroscience Research Branch
    • Translational Addiction Medicine Branch
    • Core Facilities
    • Community Outreach Group
  • Training Programs
    ▼
    • Office of Education and Career Development
    • OECD Awards
    • Summer Internship Program
    • Postbaccalaureate Program
    • Graduate Partnership Program
    • Postdoctoral Program
    • NIDA Speakers Bureau
    • Clinical Electives Program
    • Clinical Mentoring Program
  • Study Volunteers